DURECT (NASDAQ:DRRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of DURECT (NASDAQ:DRRX) in a research report issued on Sunday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating on shares of DURECT in a research note on Thursday, November 14th.

DURECT Stock Performance

Shares of DRRX stock opened at $0.78 on Friday. DURECT has a fifty-two week low of $0.70 and a fifty-two week high of $1.88. The firm has a market capitalization of $24.35 million, a price-to-earnings ratio of -1.29 and a beta of 0.91. The stock’s 50-day simple moving average is $0.83 and its 200-day simple moving average is $1.11.

Institutional Investors Weigh In On DURECT

Large investors have recently bought and sold shares of the company. Geode Capital Management LLC boosted its position in DURECT by 4.8% in the third quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock valued at $429,000 after buying an additional 14,658 shares during the last quarter. Jane Street Group LLC boosted its position in DURECT by 266.0% in the fourth quarter. Jane Street Group LLC now owns 39,196 shares of the specialty pharmaceutical company’s stock valued at $29,000 after buying an additional 28,486 shares during the last quarter. Finally, Richmond Brothers Inc. boosted its position in DURECT by 12.2% in the fourth quarter. Richmond Brothers Inc. now owns 1,281,176 shares of the specialty pharmaceutical company’s stock valued at $961,000 after buying an additional 138,920 shares during the last quarter. Hedge funds and other institutional investors own 28.03% of the company’s stock.

About DURECT

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.